Log In or Create Account
Resistance Mutations
Podcasts
Key Slides
Question of the Week
CROI
RWHAP Clinical Conference
Donate
Contact
CME Courses
HIV In-Person and Virtual Courses
Current On-Demand Courses
About Courses
CME Webinars
Upcoming Webinars
Current On-Demand Webinars
DEA-Compliant SUD Webinars
About Webinars
Dialogues
Upcoming IAS–USA Dialogues
On-Demand Dialogues
About Dialogues
Topics In Antiviral Medicine
Current Issues for CME
Previous Issues
TAM
Policies and Practices
Permission Request Form
Did You Know?
FAQs
Fellow/Student Resources
Fellow/Student Resources
IAS-USA Guidelines
On-Demand Webcasts
Research Collaborations
Additional Resources
About
Mission
Scientific Leadership Board
Core Faculty
IAS-USA Award Recipients
Staff
CME
Funding Information
Careers
Website Policies
Governance
FAQs
Menu
Topics in Antiviral Medicine
™
April 2023
Volume 31, Issue 2
Download here
, or select individual articles
Special Issue: Abstracts From the 2023 Conference on Retroviruses and Opportunistic Infections
Abstracts
Topics in Antiviral Medicine™
Current Issues
Previous Issues
TAM
Policies and Practices
TAM
Author and Contributor Guidelines
Topics in Antiviral Medicine
Editorial Board
Resistance Mutations
Podcasts
Key Slides
Question of the Week
CROI
RWHAP Clinical Conference
Donate
Contact
CME Courses
HIV In-Person and Virtual Courses
Current On-Demand Courses
About Courses
CME Webinars
Upcoming Webinars
Current On-Demand Webinars
DEA-Compliant SUD Webinars
About Webinars
Dialogues
Upcoming IAS–USA Dialogues
On-Demand Dialogues
About Dialogues
Topics In Antiviral Medicine
Current Issues for CME
Previous Issues
TAM
Policies and Practices
Permission Request Form
Did You Know?
FAQs
Fellow/Student Resources
Fellow/Student Resources
IAS-USA Guidelines
On-Demand Webcasts
Research Collaborations
Additional Resources
About
Mission
Scientific Leadership Board
Core Faculty
IAS-USA Award Recipients
Staff
CME
Funding Information
Careers
Website Policies
Governance
FAQs
Practice Question of the Week
December 4, 2023: GLP-1RA Effects in Randomized Control Trials
Glucagon-like peptide-1 receptor antagonists (GLP-1RAs) have shown several potential off-target effects. Which of the following has been demonstrated in randomized control trials?
A. GLP-1RAs reduce adverse cardiovascular outcomes in obesity among those with known atherosclerotic cardiovascular disease (ASCVD)
B. GLP-1RAs reduce adverse cardiovascular outcomes in obesity among those with and without known ASCVD
C. GLP-1RAs decrease heart failure events among those with heart failure with preserved ejection fraction and with obesity
D. GLP-1RAs reduce the severity of substance use disorders
E. All of the above
Register for the Virtual Course
View Archived Questions
Leave Feedback
Subscribe
CLOSE
